Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients

Pediatric Transplantation

Volumn 11, Issue 5, 2007, Pages 524-529

  Hmiel, S Paul ^a,b   Canter, Charles ^a   Shepherd, Ross ^a   Lassa Claxton, Sherry ^a   Nadler, Michelle ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST LOUIS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BLOOD CHEMISTRY; BLOOD PRESSURE; CARDIAC GRAFT REJECTION; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG MONITORING; DRUG SAFETY; DRUG SUBSTITUTION; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEART GRAFT; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INFECTION; LIVER FUNCTION; MALE; NEPHROTOXICITY; NEWBORN; PEDIATRIC SURGERY; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; MONITORING, PHYSIOLOGIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 34447332297     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2007.00712.x     Document Type: Article

References (22)

1. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993 : 54 : 205 218.
2. Canadian Neoral Renal Transplantation Study, G. Absorption profiling of cyclosporine microemulsion (Neoral®) during the first 2 weeks after renal transplantation. Transplantation 2001 : 72 : 1024 1032.
3. Mahalati K, Belitsky P, West K, et al. Approaching the therapeutic window for cyclosporine in kidney transplantation: A prospective study. J Am Soc Nephrol 2001 : 12 : 828 833.
4. Halloran PF, Helms LM, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999 : 68 : 1356 1361.
5. Citterio F, Scata MC, Romagnoli J, Nanni G, Castagneto M. Results of a three-year prospective study of C2 monitoring in long-term renal transplant recipients receiving cyclosporine microemulsion. Transplantation 2005 : 79 : 802 806.
6. Einecke G, Mai I, Diekmann F, et al. Optimizing Neoral therapeutic drug monitoring with cyclosporine trough (C(0)) and C(2) concentrations in stable renal allograft recipients. Transplant Proc 2001 : 33 : 3102 3103.
7. Hardinger KL, Schnitzler MA, Koch MJ, et al. Cyclosporine minimization and cost reduction in renal transplant recipients receiving a C2-monitored, cyclosporine-based quadruple immunosuppressive regimen. Transplantation 2004 : 78 : 1198 1203.
8. Mathias HC, Ozalp F, Will MB, et al. A randomized, controlled trial of C0- vs. C2-guided therapeutic drug monitoring of cyclosporine in stable heart transplant patients. J Heart Lung Transplant 2005 : 24 : 2137 2143.
9. Ray JE, Keogh AM, McLachlan AJ, Alchlaghi F. Cyclosporine C(2) and C(0) concentration monitoring in stable, long-term heart transplant recipients receiving metabolic inhibitors. J Heart Lung Transplant 2003 : 22 : 715 722.
10. Levy G, Villamil F, Samuel D, et al. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 2004 : 77 : 1632 1638.
11. Takatsuki M, Chen CL, Chen YS, et al. Impact of late conversion from C0 to C2 monitoring of microemulsified cyclosporine in pediatric living donor liver transplant recipients. Clin Transplant 2004 : 18 : 694 699.
12. Ganschow R, Richter A, Grabhorn E, et al. C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. Pediatr Transplant 2004 : 8 : 185 188.
13. Ferraresso M, Ghio L, Tirelli S, et al. Cyclosporine monitoring in stable, long-term, pediatric kidney transplant recipients: The value of C2 determination. Transplant Proc 2004 : 36 : 685 686.
14. Weber LT, Armstrong VW, Shipkova M, et al. Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection. Ther Drug Monit 2004 : 26 : 415 424.
15. Pape L, Ehrich JH, et al. Advantages of cyclosporin A using 2-h levels in pediatric kidney transplantation. Pediatr Nephrol 2004 : 19 : 1035 1038.
16. Trompeter R, Fitzpatrick M, Hutchinson C, Johnston A. Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption. Pediatr Transplant 2003 : 7 : 282 288.
17. Dunn SP. Neoral monitoring 2 hours post-dose and the pediatric transplant patient. Pediatr Transplant 2003 : 7 : 25 30.
18. Cole E, Midtvedt K, Johnston A, Pattison J, O'Grady C. Recommendations for the implementation of Neoral C(2) monitoring in clinical practice. Transplantation 2002 : 9 (Suppl. S19 S22.
19. Levy GA. C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation. BioDrugs 2001 : 15 : 279 290.
20. Cooney GF, Habucky K, Hoppu K. Cyclosporin pharmacokinetics in paediatric transplant recipients. Clin Pharmacokinet 1997 : 32 : 481 495.
21. Whitington PF, Emond JC, Whitington SH, Broelsch CE, Baker AL. Small-bowel length and the dose of cyclosporine in children after liver transplantation. N Engl J Med 1990 : 322 : 733 738.
22. Einecke G, Schutz M, Mai I, et al. Limitations of C2 monitoring in renal transplant recipients. Nephrol Dial Transplant 2005 : 20 : 1463 1470.